Table 1.
Demographic characteristics of RRMS patients and their pharmacological treatments.
| Characteristic | Mild-Moderate Disability EDSS 0–3 (n = 50) |
Severe Disability EDSS 3.5–7 (n = 25) |
p-Value |
|---|---|---|---|
| Female | 33 (66%) | 17 (68%) | NS |
| Male | 17 (34%) | 8 (32%) | NS |
| Age | 37.7 ± 11.4 | 43.0 ± 11.1 | NS |
| Years since diagnosis | 7.78 ± 5.12 | 10.2 ± 6.99 | |
| EDSS ‡ | 1.91 ± 0.88 | 4.9 ± 1.11 | * 0.00001 |
| Progression rate | 0.51 ± 0.63 | 0.99 ± 1.09 | * 0.00145 |
| Treatment: | |||
| Glatiramer Acetate | 19 (38%) | 9 (36%) | NS |
| Rituximab | 4 (8%) | 3 (12%) | |
| Interferon β | 14 (28%) | 5 (2%) | |
| Fingolimod | 5 (10%) | 2 (8%) | |
| Azathioprine | 0 | 3 (12%) | |
| Natalizumab | 1 (2%) | 1 (4%) | |
| Dimethyl fumarate | 3 (6%) | 1 (4%) | |
| None | 4 (8%) | 1 (4%) |
‡ EDSS = Expanded Disability Status Scale. Progression rate = EDSS/years with the disease. Comparisons were performed with the t-test, Mann–Whitney test, or χ2, as appropriate. * significant, NS (Not Significant).